Page last updated: 2024-11-05

4-iodophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

4-Iodophenol is an organic compound with the formula C6H4IOH. It is a white solid that is soluble in organic solvents. 4-Iodophenol is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis. 4-Iodophenol is a potent inhibitor of the enzyme tyrosine kinase. This enzyme is involved in the growth and development of cancer cells. 4-Iodophenol is also a potent antioxidant. Antioxidants protect cells from damage caused by free radicals. Free radicals are unstable molecules that can damage cells and lead to disease. 4-Iodophenol is being studied for its potential to treat a variety of diseases, including cancer, Alzheimer's disease, and Parkinson's disease. 4-Iodophenol can be synthesized by reacting phenol with iodine in the presence of a base. The reaction is typically carried out in an aqueous solution.'

Cross-References

ID SourceID
PubMed CID10894
CHEMBL ID56475
CHEBI ID43521
SCHEMBL ID5514
MeSH IDM0143439

Synonyms (57)

Synonym
AC-5105
para-iodophenol
bh194bak0b ,
unii-bh194bak0b
phenol, p-iodo-
phenol, 4-iodo-
einecs 208-745-5
4-hydroxyiodobenzene
nsc 91464
ccris 668
p-iodophenol
nsc-91464
nsc91464
540-38-5
4-iodophenol
IOL ,
4-iodophenol, 99%
4-hydroxyphenyl iodide
p-jodphenol
p-hydroxyiodobenzene
4-jodphenol
CHEBI:43521 ,
DB03002
NCIOPEN2_005594
CHEMBL56475
4-iodo-phenol
I0311
AKOS000120743
A829921
4-iodanylphenol
I0840
FT-0601339
AM20040675
p-iodophenol [who-dd]
p-iodophenol [mi]
bdbm36300
SCHEMBL5514
4-iodo phenol
p-iodo-phenol
paraiodophenol
para-iodo-phenol
dtxcid4030756
dtxsid4052186 ,
cas-540-38-5
tox21_303957
NCGC00357191-01
W-105681
mfcd00002327
STL445583
F1905-7213
GS-6844
4-iodophenol, purum, >=98.0% (gc)
4-iodphenol
Q27093973
BCP14445
EN300-21417
Z104496300
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
iodophenol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency14.38680.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency48.55770.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency50.49460.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency61.13060.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.13060.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency48.86590.001530.607315,848.9004AID1224841; AID1224848; AID1224849
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID282838Cytotoxicity against human CCRF-CEM cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID23714Partition coefficient (logP)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID23978Capacity ratio (log k'w)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID1134603Oleyl alcohol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID203473Binding constant against bovine serum albumin1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID282839Cytotoxicity against human CEM/VLB cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (10.53)18.7374
1990's8 (21.05)18.2507
2000's14 (36.84)29.6817
2010's12 (31.58)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.91 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]